A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-021-04338-7
Abstract: This study aimed at evaluating the effect of rucaparib on the pharmacokinetics of rosuvastatin and oral contraceptives in patients with advanced solid tumors and the safety of rucaparib with and without coadministration of rosuvastatin or… read more here.
Keywords: drug; rucaparib; contraceptives patients; rosuvastatin oral ... See more keywords
Rucaparib Treatment Alters p53 Oscillations in Single Cells to Enhance DNA-Double-Strand-Break-Induced Cell Cycle Arrest.
Sign Up to like & getrecommendations! Published in 2020 at "Cell reports"
DOI: 10.1016/j.celrep.2020.108240
Abstract: DNA double strand breaks induce oscillatory expression of the transcription factor p53 that is dependent on ataxia telangiectasia mutated (ATM) activity and the rate of double strand break resolution. Although p53 dynamics are known to… read more here.
Keywords: dna; rucaparib; double strand; p53 ... See more keywords
Copper-Mediated Radiosynthesis of [18F]Rucaparib.
Sign Up to like & getrecommendations! Published in 2021 at "Organic letters"
DOI: 10.1021/acs.orglett.1c02770
Abstract: The poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib is used in the clinic to treat BRCA-mutated cancers. Herein, we report two strategies to access the 18F-isotopologue of rucaparib by applying a copper-mediated nucleophilic 18F-fluorodeboronation. The most successful… read more here.
Keywords: copper mediated; mediated radiosynthesis; rucaparib; 18f rucaparib ... See more keywords
A cyanide-catalyzed imino-Stetter reaction enables the concise total syntheses of rucaparib
Sign Up to like & getrecommendations! Published in 2022 at "RSC Advances"
DOI: 10.1039/d2ra03619c
Abstract: Two routes toward the synthesis of rucaparib, an FDA-approved drug used for the treatment of ovarian and prostate cancers, have been developed from commercially available starting materials utilizing the cyanide-catalyzed imino-Stetter reaction as the key… read more here.
Keywords: stetter reaction; imino stetter; reaction; synthesis ... See more keywords
Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor
Sign Up to like & getrecommendations! Published in 2020 at "Xenobiotica"
DOI: 10.1080/00498254.2020.1737759
Abstract: Abstract 1. The absorption, distribution, metabolism, elimination, and drug-drug interaction (DDI) potential of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib was characterised in vitro. 2. Rucaparib showed moderate cellular permeability, moderate human plasma protein binding (70.2%),… read more here.
Keywords: drug; rucaparib; absorption distribution; drug drug ... See more keywords
The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2081154
Abstract: ABSTRACT Introduction In May 2020, the approval of rucaparib – a poly-ADP-ribose polymerase (PARP) inhibitor – in the USA marked the arrival of a new class of targeted therapeutics for a subset of metastatic castration-resistant… read more here.
Keywords: cancer; prostate cancer; role; management ... See more keywords
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2019-000623
Abstract: Objective To report results from an integrated efficacy and safety analysis supporting the European Commission's approval of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy treatment for relapsed, platinum-sensitive, BRCA-mutated ovarian cancer. Methods Efficacy was analyzed… read more here.
Keywords: treatment; safety; rucaparib; ovarian cancer ... See more keywords
2 Exploratory analysis of postprogression and patient-centered outcomes in ariel3: a phase 3, randomized, placebo-controlled study of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2019-igcs.2
Abstract: Objectives In ARIEL3, rucaparib maintenance treatment significantly improved progression-free survival (PFS) vs placebo. A prespecified exploratory analysis investigated postprogression outcomes. Additionally, a post hoc exploratory analysis investigated patient-centered outcomes during rucaparib maintenance treatment. Methods Patients… read more here.
Keywords: patient centered; treatment; rucaparib; placebo ... See more keywords
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2021-002933
Abstract: Background The optimal treatment strategy for women with newly diagnosed ovarian cancer has yet to be determined. Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated substantial improvement in progression-free survival as monotherapy maintenance treatment in the frontline… read more here.
Keywords: cancer; athena mono; treatment; athena combo ... See more keywords
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-16-2796
Abstract: Purpose: Rucaparib is a potent, oral, small-molecule PARP inhibitor. This phase I–II study was the first to evaluate single-agent oral rucaparib at multiple doses. Experimental Design: Part 1 (phase I) sought to determine the MTD,… read more here.
Keywords: brca1 mutated; rucaparib; parp inhibitor; phase study ... See more keywords
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation–Associated Advanced Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-17-1337
Abstract: On December 19, 2016, the FDA granted accelerated approval to rucaparib (RUBRACA; Clovis Oncology, Inc.) for the treatment of patients with deleterious BRCA mutation (germline and/or somatic)–associated advanced ovarian cancer who have been treated with… read more here.
Keywords: treatment; brca mutation; rucaparib; ovarian cancer ... See more keywords